J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

Johnson & Johnson (JNJ) announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for Spravato (esketamine) as a monotherapy for adults living with treatment-resistant depression (TRD).Spravato is presently approved in combination with an oral antidepressant to treat adults with TRD and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.Following the latest nod, Spravato became the first and only monotherapy fo ...